The therapeutic community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s exhibiting significant efficacy in clinical trials for treating obesity. Unlike some existing weight loss treatments, retatrutide appears to offer a greater substantial decrease in body size and benefit metabolic health, partic